Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP16 for SARS-CoV-2 Induced ARDS
NCT05135624Phase 1Terminated
- Sponsor
- Serpin Pharma
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SP16 in Coronavirus Disease 2019 (COVID-19) and pneumonia (3 arms), sponsored by Serpin Pharma. Primary endpoints: Safety and tolerability of SP16 at 14 days, Change in inflammatory cytokines at 14 days and 1 more. Started Dec 2021; status: terminated.
02
Drugs
SP16
03
Conditions
Coronavirus Disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on NCT05135624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135624.